Filing Details
- Accession Number:
- 0000059478-25-000039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-12 16:15:38
- Reporting Period:
- 2025-02-10
- Filing Date:
- 2025-02-12
- Accepted Time:
- 2025-02-12 16:15:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 59478 | Eli Lilly & Co | LLY | Pharmaceutical Preparations (2834) | 350470950 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1741474 | Daniel Skovronsky | Lilly Corporate Center Indianapolis IN 46285 | Evp, Cso & Pres. Lrl & Lly Imm | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2025-02-10 | 3,950 | $862.69 | 118,938 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-02-10 | 340 | $863.97 | 118,598 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-02-10 | 710 | $865.76 | 117,888 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-10 | 18,772 | $868.88 | 136,660 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Acquisiton | 2025-02-10 | 12,684 | $0.00 | 12,684 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 12,684 | 2026-02-01 | 2026-02-01 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 72,359 | Indirect | By Trust |
| Common Stock | 3,257 | Indirect | By spouse |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Billionaire Hedge Funds
